How had Indian Pharma responded to the challenges brought on by the Covid19 crisis and the inability to connect with doctors and other Rx influencers? Is it back to business-as-usual or have some companies learned from their mistakes and become digital savvy? How will Indian Pharma cope with the possibility of another lockdown and meeting restrictions looming in view of the rising Omicron wave?

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution

In the blistering Sonoran Desert, where temperatures regularly exceed...

The Quiet Crisis in the Indian Pharma Field Force

A MedicinMan Editorial based on the Poll framed by...

The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience

A recent industry spotlight by Venkat Mutavi notes a...

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Marketing

Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution

In the blistering Sonoran Desert, where temperatures regularly exceed...

The Quiet Crisis in the Indian Pharma Field Force

A MedicinMan Editorial based on the Poll framed by...

The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience

A recent industry spotlight by Venkat Mutavi notes a...

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Policies/Sales

Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution

In the blistering Sonoran Desert, where temperatures regularly exceed...

The Quiet Crisis in the Indian Pharma Field Force

A MedicinMan Editorial based on the Poll framed by...

The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience

A recent industry spotlight by Venkat Mutavi notes a...

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Strategy

Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution

In the blistering Sonoran Desert, where temperatures regularly exceed...

The Quiet Crisis in the Indian Pharma Field Force

A MedicinMan Editorial based on the Poll framed by...

The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience

A recent industry spotlight by Venkat Mutavi notes a...

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Eli Lilly’s $6.5 Billion Houston Bet: A Strategic Play in U.S. Manufacturing, Policy, and the Next Wave of Obesity Treatment

When Eli Lilly announced plans to build a $6.5...

MedicinMan Steps into Year Five

Articles by K. Hariram, Daxesh Patel, Gopal Kishore, Amit Jain, Sunil Bajaj and Vivek Hattangadi

Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead

The latest PharmaTrac report for December 2025 offers a...

Interview with Ajit Singh, Chairman, ACG

Special interview with the Chairman of ACG and an invitation to "Pharmaceutical Marketing in the New Age" - a conference presented by ACG in partnership with MedicinMan

DigiStorm 2018: Intent, Content, Strategy and Skills

The pharma industry in India is entering a very interesting variant of the post-digital marketing era. The term “post-digital marketing” is used to depict a state where the lines between physical and digital blur considerably for a customer. However, in the context of pharma, this means a state where the industry has stopped questioning the need for digital and has begun to implement very interesting digital marketing initiatives.